

Reference: FOI.ICB-2627/178

Subject: Asthma/COPD Pathway Formulary Review and Renewal Dates

I can confirm that the ICB does hold some of the information requested; please see responses below:

QUESTION	RESPONSE
I would be grateful if you could provide the following information relating to your ICB's asthma/COPD pathways and associated formularies:	
1. The current review, renewal, or scheduled update date for any spacer device formulary recommendations used within your asthma/COPD pathway.	BNSSG (Bristol, North Somerset and South Gloucestershire) ICB does not maintain a spacer device formulary, However, spacer device requirements are considered as part of the scheduled review process for respiratory guidelines to ensure recommendations remain clinically appropriate and aligned with current evidence. • BNSSG Asthma Guidelines 2025 (16 years+): March 2028 • BNSSG COPD Management Guidelines 2025: December 2027 • BNSSG Asthma Guideline 2025 – Children & Young People (CYP): August 2025
2. The current review, renewal, or scheduled update date for any peak flow meter formulary recommendations used within your asthma/COPD pathway.	The ICB does not maintain a peak flow meter formulary, However, peak flow meter requirements are considered as part of the scheduled review process for respiratory guidelines to ensure recommendations remain clinically appropriate and aligned with current evidence. • BNSSG Asthma Guidelines 2025 (16 years+): March 2028 • BNSSG COPD Management Guidelines 2025: December 2027 • BNSSG Asthma Guideline 2025 – Children & Young People (CYP): August 2025

3. Where applicable, the name of the committee, group, or governance body responsible for reviewing and approving these formulary decisions.	BNSSG Joint Formulary Group
4. The anticipated timeline for the next review of the spacer and peak flow sections of the formulary, if known.	The spacer device and peak flow meter sections will be reviewed as part of the scheduled respiratory guideline updates outlined above.
5. In addition, I would be grateful if you could provide the appropriate contact details for the individual(s) or team(s) responsible for receiving evidence and product information submissions relating to formulary reviews, including: i. Name ii. Job title iii. Email address iv. Organisation/committee name	Formulary Team bnssg.formulary@nhs.net BNSSG Joint Formulary Group

The information provided in this response is accurate as of 29 July 2026 and has been approved for release by Dr Aananthakrishnan Raghuram, Chief Clinical Leadership and Delivery Officer (Medical) for NHS Bristol, North Somerset and South Gloucestershire ICB.